01:02 PM EDT, 03/14/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) shares were down over 2% in recent Friday trading after multiple media reports said that a US appeals court denied the company's request to block sales of biosimilar versions of its drug Eylea.

The company was seeking to prevent Amgen ( AMGN ) and others from marketing copy-cat versions of its treatment for wet macular degeneration but the US Court of Appeals for the Federal Circuit upheld an earlier decision to deny Regeneron's motion for patent infringement.

The earlier motion was denied on grounds that the company could not prove Amgen ( AMGN ) infringed on Regeneron's patents covering a vial containing Eylea, according to reports.

Price: 664.59, Change: -16.02, Percent Change: -2.35